KOL Perception on Crohn's Disease: How Precision Medicine, AI, and Next-Generation Therapies Are Shaping the Future of IBD Management
Insights from 50 Key Opinion Leaders across the United States and Europe on unmet needs, innovation, biomarker-guided care, AI, and the future of Crohn's disease management.
To assess expert perceptions regarding the current management of Crohn's disease, emerging therapeutic innovations, biologic and small-molecule treatments, precision medicine, unmet clinical needs, and future treatment directions in inflammatory bowel disease.
Why the treatment landscape is still evolving
Despite remarkable progress in biologic therapies over the past decade, Crohn's disease treatment continues to present significant clinical challenges. While targeted biologics and oral therapies have improved patient outcomes, healthcare providers still struggle with achieving sustained remission, preventing disease progression, optimizing treatment sequencing, and improving long-term quality of life.
As the prevalence of Inflammatory Bowel Disease continues to rise globally, there is increasing demand for more precise, personalized, and technology-enabled approaches to patient care.
To better understand this evolving landscape, a recent Healthcare Market Research study surveyed 50 Key Opinion Leaders across the United States and Europe to capture their views on recent progress, persistent gaps, and the innovations expected to shape the next decade of care.
Experts are focused on durable remission, better sequencing, reduced disease progression, and improved quality of life.
Precision medicine, biomarkers, therapeutic drug monitoring, and AI are central to the future treatment model.
Key Outcome Summary
This section keeps the strong visual style you liked, while the rest of the page is rebuilt to feel cleaner, more premium, and easier to scan.
Strong consensus that significant unmet needs remain despite major advances in biologic and targeted therapies.
Biomarker-guided treatment and precision medicine are viewed as extremely important for optimization.
Most experts believe treatment options will expand substantially within the next 5 years.
The long-term outlook is optimistic, driven by therapeutic innovation and more personalized care pathways.
Crohn's disease still presents major treatment barriers
Although biologic therapies targeting TNF-α, IL-12/23, and integrin pathways have improved outcomes, specialists still believe unmet medical needs remain substantial.
The survey found that 84% of KOLs believe the unmet need is still high, while 78% feel current treatment options are only partially adequate.
Only 10% consider existing therapies sufficient to address today's clinical challenges, underscoring the need for more durable and personalized approaches.
Loss of response over time
Durable remission remains difficult, with many patients losing therapeutic response after initial benefit.
Primary non-response
Not all patients respond to biologics, which limits confidence in current first-line and follow-on strategies.
Disease progression
Progression can continue despite treatment, especially in patients with complex or aggressive disease phenotypes.
Fibrotic and fistulizing disease
These manifestations remain difficult to manage and continue to represent areas of substantial unmet need.
Treatment sequencing
Clinicians face growing complexity when selecting, sequencing, and switching biologics and oral therapies.
Safety and access barriers
Long-term safety concerns and reimbursement limitations continue to affect real-world treatment access and decisions.
Survey Results Summary
The data section is now redesigned to feel more like a polished insight dashboard instead of a plain report table.
Experts are optimistic or very optimistic about future treatment outcomes over the next decade.
See a very high or high need for improved Crohn's disease therapies.
Say available biologics and targeted therapies are only partially adequate.
Rate biomarker-guided treatment and precision medicine as extremely important.
Believe AI and digital health tools are likely to improve management and treatment selection.
Most common response by question
Unmet need remains high
Most common response: Very High / High unmet need.
Current therapies are only partly adequate
Most common response: Additional innovation is still needed.
Innovation is centered on biologics and small molecules
Most common response: Advanced biologics and selective small molecules.
Precision medicine is now central
Most common response: Biomarker-guided treatment is extremely important.
Therapeutic options are expected to expand
Most common response: Yes, options will expand substantially in the next 5 years.
Sequencing and loss of response are the biggest barriers
Most common response: Loss of response and treatment sequencing challenges.
AI is seen as clinically useful
Most common response: AI and digital health tools are likely or very likely to help.
Future outlook is highly optimistic
Most common response: Optimistic / Very optimistic over the next decade.
Response Distribution by Question
Instead of plain text blocks, the response distribution is grouped into cleaner insight cards with stronger hierarchy.
Q1 to Q4
Q5 to Q8
A more integrated future for IBD management
This Healthcare Market Research highlights a strong consensus among experts that while remarkable progress has been made in Crohn's disease treatment, considerable opportunities remain to improve long-term patient outcomes.
The survey confirms that Precision Medicine, Biologic Therapies, Small Molecule Therapies, Biomarker-Guided Treatment, and Therapeutic Drug Monitoring are becoming fundamental components of modern Crohn's disease management.
The findings also reinforce the growing importance of AI in Healthcare, digital innovation, and Personalized Medicine in shaping the future of Crohn's disease therapies, enabling earlier intervention, more accurate treatment selection, and improved disease monitoring.
Strategic takeaway
Organizations that embrace therapeutic innovation, data-driven decision-making, and patient-centered care will be better positioned to improve outcomes and deliver lasting value in inflammatory bowel disease.
